Przemek A Gorski1, Seung Pil Jang2, Dongtak Jeong1, Ahyoung Lee1, Philyoung Lee1, Jae Gyun Oh1, Vadim Chepurko1, Dong Kwon Yang2, Tae Hwan Kwak3, Soo Hyun Eom2, Zee-Yong Park2, Yung Joon Yoo2, Do Han Kim2, Hyun Kook4, Yoichi Sunagawa5, Tatsuya Morimoto5, Koji Hasegawa6, Junichi Sadoshima7, Peter Vangheluwe8, Roger J Hajjar1, Woo Jin Park2, Changwon Kho1. 1. From the Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York (P.A.G., D.J., A.L., P.L., J.G.O., V.C., R.J.H., C.K.). 2. College of Life Sciences, Gwangju Institute of Science and Technology, Korea (S.P.J., D.K.Y., S.H.E., Z.-Y.P., Y.J.Y., D.H.K., W.J.P.). 3. NADIAN BIO Ltd, Iksan, Jeonbuk, Korea (T.H.K.). 4. Basic Research Laboratory, Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Korea (H.K.). 5. Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Japan (Y.S., T.M.). 6. Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, Japan (K.H.). 7. Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (J.S.). 8. Department of Cellular and Molecular Medicine, KU Leuven, Belgium (P.V.)
Abstract
RATIONALE: SERCA2a, sarco-endoplasmic reticulum Ca2+-ATPase, is a critical determinant of cardiac function. Reduced level and activity of SERCA2a are major features of heart failure. Accordingly, intensive efforts have been made to develop efficient modalities for SERCA2a activation. We showed that the activity of SERCA2a is enhanced by post-translational modification with SUMO1 (small ubiquitin-like modifier 1). However, the roles of other post-translational modifications on SERCA2a are still unknown. OBJECTIVE: In this study, we aim to assess the role of lysine acetylation on SERCA2a function and determine whether inhibition of lysine acetylation can improve cardiac function in the setting of heart failure. METHODS AND RESULTS: The acetylation of SERCA2a was significantly increased in failing hearts of humans, mice, and pigs, which is associated with the reduced level of SIRT1 (sirtuin 1), a class III histone deacetylase. Downregulation of SIRT1 increased the SERCA2a acetylation, which in turn led to SERCA2a dysfunction and cardiac defects at baseline. In contrast, pharmacological activation of SIRT1 reduced the SERCA2a acetylation, which was accompanied by recovery of SERCA2a function and cardiac defects in failing hearts. Lysine 492 (K492) was of critical importance for the regulation of SERCA2a activity via acetylation. Acetylation at K492 significantly reduced the SERCA2a activity, presumably through interfering with the binding of ATP to SERCA2a. In failing hearts, acetylation at K492 appeared to be mediated by p300 (histone acetyltransferase p300), a histone acetyltransferase. CONCLUSIONS: These results indicate that acetylation/deacetylation at K492, which is regulated by SIRT1 and p300, is critical for the regulation of SERCA2a activity in hearts. Pharmacological activation of SIRT1 can restore SERCA2a activity through deacetylation at K492. These findings might provide a novel strategy for the treatment of heart failure.
RATIONALE: SERCA2a, sarco-endoplasmic reticulum Ca2+-ATPase, is a critical determinant of cardiac function. Reduced level and activity of SERCA2a are major features of heart failure. Accordingly, intensive efforts have been made to develop efficient modalities for SERCA2a activation. We showed that the activity of SERCA2a is enhanced by post-translational modification with SUMO1 (small ubiquitin-like modifier 1). However, the roles of other post-translational modifications on SERCA2a are still unknown. OBJECTIVE: In this study, we aim to assess the role of lysine acetylation on SERCA2a function and determine whether inhibition of lysine acetylation can improve cardiac function in the setting of heart failure. METHODS AND RESULTS: The acetylation of SERCA2a was significantly increased in failing hearts of humans, mice, and pigs, which is associated with the reduced level of SIRT1 (sirtuin 1), a class III histone deacetylase. Downregulation of SIRT1 increased the SERCA2a acetylation, which in turn led to SERCA2a dysfunction and cardiac defects at baseline. In contrast, pharmacological activation of SIRT1 reduced the SERCA2a acetylation, which was accompanied by recovery of SERCA2a function and cardiac defects in failing hearts. Lysine 492 (K492) was of critical importance for the regulation of SERCA2a activity via acetylation. Acetylation at K492 significantly reduced the SERCA2a activity, presumably through interfering with the binding of ATP to SERCA2a. In failing hearts, acetylation at K492 appeared to be mediated by p300 (histone acetyltransferase p300), a histone acetyltransferase. CONCLUSIONS: These results indicate that acetylation/deacetylation at K492, which is regulated by SIRT1 and p300, is critical for the regulation of SERCA2a activity in hearts. Pharmacological activation of SIRT1 can restore SERCA2a activity through deacetylation at K492. These findings might provide a novel strategy for the treatment of heart failure.
Authors: Ralph R Alcendor; Shumin Gao; Peiyong Zhai; Daniela Zablocki; Eric Holle; Xianzhong Yu; Bin Tian; Thomas Wagner; Stephen F Vatner; Junichi Sadoshima Journal: Circ Res Date: 2007-04-19 Impact factor: 17.367
Authors: Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini Journal: Am J Physiol Cell Physiol Date: 2022-02-09 Impact factor: 4.249
Authors: Mahmoud Abdellatif; Viktoria Trummer-Herbst; Franziska Koser; Sylvère Durand; Rui Adão; Francisco Vasques-Nóvoa; Johanna K Freundt; Julia Voglhuber; Maria-Rosaria Pricolo; Michael Kasa; Clara Türk; Fanny Aprahamian; Elías Herrero-Galán; Sebastian J Hofer; Tobias Pendl; Lavinia Rech; Julia Kargl; Nathaly Anto-Michel; Senka Ljubojevic-Holzer; Julia Schipke; Christina Brandenberger; Martina Auer; Renate Schreiber; Chintan N Koyani; Akos Heinemann; Andreas Zirlik; Albrecht Schmidt; Dirk von Lewinski; Daniel Scherr; Peter P Rainer; Julia von Maltzahn; Christian Mühlfeld; Marcus Krüger; Saša Frank; Frank Madeo; Tobias Eisenberg; Andreas Prokesch; Adelino F Leite-Moreira; André P Lourenço; Jorge Alegre-Cebollada; Stefan Kiechl; Wolfgang A Linke; Guido Kroemer; Simon Sedej Journal: Sci Transl Med Date: 2021-02-10 Impact factor: 19.319